ESPR - Approval of NEXLETOL (Cardiovascular Diseases)

Mar 23

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

This is not a financial advice!

03/22/24

U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

We haven't really seen a big push of the stock price of this news yet.

Recent block buys

Short Float 10.06%

We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.

We need to break and stay above 2.6-2.7 area before entering a trade.

Keep an eye on 3.0 level, needs to get broken for a further upmove. You can take partial profits at this level if u want to lock in gains.

SL under 1.9

TPs approx. 4.4 or even 5.2

Most info on the chart.

Trade carefully!

Apr 2

Note

ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m. ET today, April 1, 2024, to commemorate the U.S. Food and Drug Administration's (FDA) recent approval of broad new labels for Esperion's products.

May 19

Trade closed: stop reached